Epidermal Growth Factor Side Effects: What Studies Report

What the phrase "epidermal growth factor side effects" covers in the indexed literature

Epidermal growth factor (EGF) is a small signalling protein that binds the epidermal growth factor receptor (EGFR), a member of the ErbB/HER receptor family that also includes HER2, formally named human epidermal growth factor receptor 2. In the medical literature, the phrase "epidermal growth factor" appears far more often inside receptor and drug-class names — anti-epidermal growth factor receptor targeted therapy, human epidermal growth factor receptor 2-directed antibody-drug conjugate — than as the name of an administered substance. The consequence is straightforward: when safety data are indexed under this phrase, they usually describe the adverse events of agents that block or target the pathway, not the adverse events of EGF given to a person.

That difference is pharmacologically important. Blocking a receptor and supplying its ligand are opposite interventions, and the adverse-event profile of one cannot be read across to the other. This page therefore organises the published material by what was actually studied — the receptor-targeted drug, the population, and the events researchers recorded — and separately notes where the verified literature contains no human data at all. Readers looking for receptor biology, ligand binding and downstream signalling rather than safety reporting will find that material in PeptideU's introductory epidermal growth factor course; this page stays with what safety papers reported.

Skin and Mucosal Findings With EGFR-Targeted Agents: What Studies Report

EGFR is expressed in skin and in the epithelial lining of the gastrointestinal tract, which is the anatomical reason dermatologic and mucosal events dominate the anti-EGFR safety literature. A 2024 report in Oral Oncology described ulcerations of skin and mucosa occurring in association with anti-epidermal growth factor receptor targeted therapy, framing them as a recognisable class effect requiring clinical recognition (PMID 38086198). The same paper presented these ulcerations as distinct from the more familiar papulopustular eruption, which is why researchers argued they merit separate description (PMID 38086198).

Skin findings also appeared where an anti-EGFR antibody was combined with a targeted small molecule. In a phase 1b trial of sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer, researchers reported dermatologic toxicity among the treatment-related adverse events observed with the combination (PMID 38177853). The study was designed to characterise safety and preliminary activity of that combination rather than to compare it against a control arm (PMID 38177853).

Preclinical work has looked at the same two tissues. A mouse lung-cancer model published in 2024 examined adverse effects of the EGFR tyrosine kinase inhibitor gefitinib and reported changes in skin and colon in the treated animals (PMID 37723963). That the study selected skin and colon as its endpoints reflects the clinical pattern seen with EGFR inhibition in people, and the authors framed the model as a way to study those effects experimentally (PMID 37723963).

Lung Findings With HER2-Directed Therapy: What Studies Report

HER2-directed antibodies and conjugates carry their own organ-specific signals. A 2023 case report in Cureus described interstitial pneumonitis that the authors attributed to trastuzumab, an antibody directed at human epidermal growth factor receptor 2 (PMID 37602136). A single case report establishes that an event occurred and was recognised; it does not establish how often it occurs, and the publication format itself signals rarity rather than frequency (PMID 37602136).

Broader synthesis of this class came from a 2025 review in Therapeutic Advances in Medical Oncology, which catalogued toxicities and management strategies for emerging antibody-drug conjugates used in breast cancer (PMID 40151551). Reviews of this kind aggregate what individual trials reported and set out monitoring approaches, so their value is organisational rather than as a new source of incidence data (PMID 40151551).

Early-Phase Conjugate Trials: What Studies Report

Early-phase oncology trials are where safety is formally characterised before efficacy questions are settled. A global phase I trial of SHR-A1811, a human epidermal growth factor receptor 2-directed antibody-drug conjugate, reported safety, efficacy and pharmacokinetics in patients with HER2-expressing or HER2-mutated advanced solid tumours (PMID 38900984). The study covered dose escalation and expansion across tumour types, which is the standard structure for defining a dose to carry into later trials (PMID 38900984).

A parallel example outside the HER2 class illustrates how phase 1 safety reporting works. In a phase 1 trial of a lysine acetyltransferase KAT6 inhibitor in ER-positive, HER2-negative metastatic breast cancer, researchers reported dysgeusia — an altered sense of taste — and neutropenia among the treatment-related adverse events observed (PMID 38824244). The point of citing it here is structural: each targeted mechanism produces its own adverse-event signature, and HER2-negative status defined the population studied in that trial (PMID 38824244).

Regimen De-escalation and Reported Toxicity: What Studies Report

Some of the most direct safety comparisons come from trials that remove a drug from an established regimen. The randomised noninferiority phase III neoCARHP trial compared neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive breast cancer, and researchers reported that omitting carboplatin was noninferior for the pathologic complete response endpoint (PMID 41576297). The study's design — a head-to-head randomisation differing by one agent — is what allows a difference in reported adverse events to be attributed to that agent rather than to the backbone therapy (PMID 41576297).

Animal and Ocular Studies: What Studies Report

Animal work occupies a distinct tier of evidence. A 2022 study in Scientific Reports evaluated the safety and tolerability of intravitreal cetuximab, an anti-EGFR antibody, in young and adult rabbits (PMID 35794227). The study asked whether an EGFR-blocking antibody could be delivered into the eye without ocular injury in that species, and its findings describe rabbits rather than people (PMID 35794227). The same caveat applies to the gefitinib mouse model described above, where skin and colon effects were observed in animals (PMID 37723963).

Adjacent Agents in HER2-Defined Populations: What Studies Report

Because HER2 status defines trial eligibility across breast oncology, papers naming "human epidermal growth factor receptor 2" often describe drugs with no relationship to the EGF pathway. Their safety data are reported alongside HER2 terminology and can be mistaken for pathway effects. The OlympiAD trial reported final overall survival and tolerability results for olaparib versus chemotherapy of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (PMID 30689707). Its tolerability comparison concerned a PARP inhibitor against chemotherapy, not an EGFR-targeted agent (PMID 30689707).

Safety and patient-reported outcomes from the monarchE study of adjuvant abemaciclib combined with endocrine therapy in high-risk early breast cancer described diarrhoea among the adverse events recorded with that combination (PMID 35337972). A real-world analysis of alpelisib in breast cancer reported hyperglycaemia among the adverse events encountered outside the controlled trial setting (PMID 35450470). Both papers are useful for understanding how oncology safety data are collected and graded; neither reports on EGF or on EGFR blockade (PMID 35337972, PMID 35450470).

Summary of the cited findings

What this literature does not report

The verified set summarised here contains no human trial that administered epidermal growth factor itself, by any route, at any dose. There is therefore no dosing information, no adverse-event frequency and no exposure duration for EGF as an administered peptide in these papers, and none is offered on this page. Claims about EGF's tolerability in people cannot be supported by studies of drugs that inhibit its receptor — the mechanism runs in the opposite direction, and the adverse events described in those papers are consequences of blockade.

Several further gaps follow from the same limitation:

• No long-term follow-up of EGF administration in humans appears in this set.
• Topical and cosmetic uses of EGF-labelled preparations are not covered by any of the cited papers.
• The ocular data available here come from rabbits, and describe an EGFR-blocking antibody rather than EGF (PMID 35794227).
• Skin and colon findings in the murine model were observed in mice given an EGFR inhibitor, not in people (PMID 37723963).

How the evidence tiers differ

Reading this literature accurately means keeping the study designs separate. A case report documents that an event happened once and was noticed, as with the pneumonitis description attributed to trastuzumab (PMID 37602136). A phase 1 or phase 1b trial characterises adverse events in a small, selected group, as in the sotorasib-plus-panitumumab study (PMID 38177853) and the phase I conjugate study (PMID 38900984). A randomised phase III trial can attribute a difference to a single agent because the arms differ by that agent alone (PMID 41576297). A real-world analysis captures what occurred in routine practice, where populations are less selected than in trials (PMID 35450470). A narrative review organises the output of the other tiers without generating new incidence figures (PMID 40151551). None of these tiers is interchangeable with another, and none of them substitutes for a human study of EGF itself, which the verified set does not contain.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, symptom or treatment decision. Nothing here describes a protocol, and the adverse events summarised above belong to prescription oncology agents administered under clinical supervision in the trials and reports cited.

References

• Anti-epidermal growth factor receptor targeted therapy-associated ulcerations (Oral Oncology, 2024)
• Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial (Nature Medicine, 2024)
• Adverse Effects of Gefitinib on Skin and Colon in a Lung Cancer Mouse Model (Recent Patents on Anti-Cancer Drug Discovery, 2024)
• Trastuzumab-Induced Interstitial Pneumonitis (Cureus, 2023)
• Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer (Therapeutic Advances in Medical Oncology, 2025)
• Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial (Journal of Clinical Oncology, 2024)
• Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial (Nature Medicine, 2024)
• Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial (Journal of Clinical Oncology, 2026)
• Safety and tolerability of intravitreal cetuximab in young and adult rabbits (Scientific Reports, 2022)
• OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (Annals of Oncology, 2019)
• Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study (Annals of Oncology, 2022)
• The efficacy and safety of alpelisib in breast cancer: A real-world analysis (Journal of Oncology Pharmacy Practice, 2022)